Clinical trials: Epirubicin
Breast Cancer
Combination Chemotherapy in Treating Women With Stage I Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00055679
- Testing
- cyclophosphamide, epirubicin hydrochloride, fluorouracil
- Where
- 72 sites in France
- Volunteers
- 1,512 people
- Sponsor
- UNICANCER
Breast Cancer
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
This study is a randomized, single center, phase III clinical trial comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of docetaxel (EC*4-T*4) verses 6 cycles of…
- Trial name
- PANSY (NCT04193059)
- Testing
- Paclitaxel, Carboplatin, Epirubicin
- Where
- China
- Volunteers
- 1,560 people
- Sponsor
- Fudan University
Breast Neoplasms, Triple Negative Breast Neoplasms
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Researchers are looking for new ways to treat types of breast cancer that are both: High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment Early-stage, which means the cancer is…
- Conditions
- Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
- Trial name
- NCT06966700
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication
- Where
- 331 sites in United States, Argentina and 39 more
- Volunteers
- 2,400 people
- Sponsor
- Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
The purpose of this trial is to compare the 3-year disease-free survival of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy for triple-negative breast cancer…
- Trial name
- NCT03876886
- Testing
- Epirubicin, Cyclophosphamide, Paclitaxel
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations
The purpose of this study is to compare the efficiency and safety between paclitaxel combined with epirubicin and vinorelbine combined with epirubicin when used in neoadjuvant chemotherapy for locally advanced (IIb-IIIc)…
- Trial name
- NCT02628613
- Testing
- Vinorelbine plus Epirubicin, Paclitaxel plus Epirubicin
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Fudan University
Metastatic/Recurrent Breast Cancer
Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer
This is a Phase I, multi-centre, open-label, cross-over pharmacokinetic study designed to investigate whether the co-administration of a fixed dose of tesmilifene alters the plasma pharmacokinetics of a standard regimen of…
- Trial name
- NCT00364754
- Testing
- Tesmilifene (YMB 1002)
- Where
- 10 sites in Georgia, Russia and 1 more
- Volunteers
- 28 people
- Sponsor
- YM BioSciences
Breast Neoplasms, Alopecia
Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients
Chemotherapy-induced alopecia (CIA) significantly compromises body image in breast cancer patients, particularly when involving eyebrow and eyelash loss (madarosis).
- Conditions
- Breast Neoplasms, Alopecia, Madarosis, Eyebrow Diseases
- Trial name
- NCT06955702
- Testing
- cryotherapy for chemotherapy-induced madarosis
- Where
- 2 sites in Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Salamanca
Breast Cancer
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Phase II randomized multicenter trial to compare Epirubicin and Cyclophosphamide plus Docetaxel and Trastuzumab with Epirubicin and Cyclophosphamide plus Docetaxel and Lapatinib for patients with positive HER2 and resectable or…
- Trial name
- NCT00841828
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- 26 sites in Spain
- Volunteers
- 102 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer, Chemotherapy Effect
Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer
Comparison of docetaxel and Nab-paclitaxel in neoadjuvant chemotherapy for breast cancer
- Trial name
- NCT05251766
- Testing
- Nab paclitaxel, Docetaxel
- Volunteers
- 30 people
- Sponsor
- Xuli Meng
Breast Cancer
An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment
For many years scientists and cancer researchers have been trying to find out why some people benefit more from anti-cancer medications than other people who receive the same amount and same kind of medications.
- Trial name
- NCT00131612
- Testing
- FEC 100
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- AHS Cancer Control Alberta
Primary Breast Cancer, Her2 Non-overexpressing
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
The planned trial compares an anthracycline-free taxane based regimen versus a modern third generation (anthracycline/taxane-based) regimen in HER2/neu non-over expressing tumors.
- Trial name
- planB (NCT01049425)
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- Germany
- Volunteers
- 3,198 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00629278
- Testing
- trastuzumab, aromatase inhibition therapy, cyclophosphamide
- Where
- 6 sites in Italy
- Volunteers
- 2,500 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Testicular Neoplasms
GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
St Bartholomew's hospital completed a study using the regimen GAMEC (PEG-filgrastim, actinomycin-D, methotrexate, etoposide, cisplatin).
- Trial name
- GAMEC-II (NCT06309732)
- Testing
- Pegfilgrastim, Dactinomycin, Methotrexate
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Queen Mary University of London
Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells following…
- Trial name
- NCT00047099
- Testing
- cyclophosphamide, docetaxel, epirubicin hydrochloride
- Where
- 2 sites in Germany
- Volunteers
- 446 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Bladder Cancer
Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Drugs used in chemotherapy, such as mitomycin C and epirubicin hydrochloride, work in different ways to stop the…
- Trial name
- NCT01094964
- Testing
- BCG solution, recombinant interferon alfa, epirubicin hydrochloride
- Where
- 9 sites in United Kingdom
- Volunteers
- 242 people
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Stomach Cancer, Gastric Cancer
Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
The main purpose of this trial is to determine how well patients with gastric or gastroesophageal junction adenocarcinoma respond to chemotherapy with epirubicin, cisplatin and 5-fluorouracil followed by continuous infusion…
- Conditions
- Stomach Cancer, Gastric Cancer, Gastro-esophageal Junction Cancer
- Trial name
- NCT00215514
- Testing
- Epirubicin, Cisplatin, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Triple-negative Breast Cancer
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Triple negative breast cancer (TNBC), characterized by estrogen receptor, progesterone receptor and HER2 negative, accounts for 10-20% of all breast cancers and usually occurs in young women.
- Trial name
- NCT04213898
- Testing
- SHR-1210+Albumin-bound paclitaxel + epirubicin
- Volunteers
- 39 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer
Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004873
- Testing
- cisplatin, docetaxel, epirubicin hydrochloride
- Where
- Switzerland
- Sponsor
- Swiss Cancer Institute
Carcinoma, Hepatocellular
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Primary Objective: To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE. Secondary Objectives: 1. To determine the progression-free survival of TACE vs.
- Trial name
- NCT01327521
- Testing
- CyberKnife, TACE, CT Contrast
- Where
- United States
- Sponsor
- Albert Koong
Breast Cancer, Triple Negative Breast Cancer
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial
Italian, multicenter, open-label, two-arm, comparative, randomized phase II study investigating if the addition of the experimental metabolic intervention consisting in cycles of Fasting-Like Approach, as administered every three…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Dietary Exposure, Fasting
- Trial name
- BREAKFAST-2 (NCT05763992)
- Testing
- Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)
- Where
- Italy
- Volunteers
- 145 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano